Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
---|---|---|---|---|---|---|
2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 2 | 1 | |
2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 4 | |
2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 618 | 595 | |
2006 | Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy | DA-LIANG OU ; Chen C.-L.; Lin S.B.; CHIH-HUNG HSU ; LIANG-IN LIN | Journal of Pathology | 61 | 52 | |
2002 | The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells | Hergenhahn M.; Soto U.; Weninger A.; Polack A.; CHIH-HUNG HSU ; ANN-LII CHENG ; Rösl F. | Molecular Carcinogenesis | 70 | 61 | |
2014 | Clinical activity of metronomic chemotherapy in liver cancers | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Metronomic Chemotherapy: Pharmacology and Clinical Applications | 0 | 0 | |
2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
2007 | Clinical studies with curcumin | CHIH-HUNG HSU ; ANN-LII CHENG | Advances in Experimental Medicine and Biology | 359 | 305 | |
1993 | Cloning and expression of the gene encoding Acacia confusa trypsin inhibitor that is active without post-translational proteolysis | CHIH-HUNG HSU ; Ming-Chih L.; Ming-Tay L.; Jung-Yaw L. | Gene | 15 | 14 | |
2001 | Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma | CHIH-HUNG HSU ; Chen J.; Wu C.-Y.; ANN-LII CHENG ; YEONG-SHIAU PU | Anticancer Research | 27 | 24 | |
2002 | Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma | Huang C.-L.; ZHONG-ZHE LIN ; Su I.-J.; Chao T.-Y.; HWEI-FANG TIEN ; Chang M.-C.; Huang M.-C.; Kao W.-Y.; JIH-LUH TANG ; KUN-HUEI YEH ; Wang C.-H.; CHIH-HUNG HSU ; Liu M.-Y.; ANN-LII CHENG | Leukemia and Lymphoma | 9 | 5 | |
2010 | Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma | Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; SUNG-HSIN KUO ; CHIH-HUNG HSU ; YEN-SHEN LU ; ANN-LII CHENG | Cancer Letters | 19 | 19 | |
2012 | Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma | Yen T.-J.; Chung C.-S.; YEN-WEN WU ; RUOH-FANG YEN ; MEI-FANG CHENG ; JANG-MING LEE ; CHIH-HUNG HSU ; YIH-LEONG CHANG ; HSIU-PO WANG | Diseases of the Esophagus | 33 | 30 | |
2007 | Comparison of the phosphorylation of 4′-ethynyl 2′,3′- dihydro3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs | CHIH-HUNG HSU ; Hu R.; Dutschman G.E.; Yang G.; Krishnan P.; Tanaka H.; Baba M.; Cheng Y.-C. | Antimicrobial Agents and Chemotherapy | 14 | 13 | |
2006 | Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study | CHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU | Anticancer Research | 0 | 0 | |
1999 | Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil | CHIH-HUNG HSU ; KUN-HUEI YEH ; Lui L.T.; Lee Y.-C.; Bu C.-F.; HSIU-PO WANG ; Lin J.-T.; ANN-LII CHENG | Anticancer Research | 29 | 26 | |
2007 | Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C. | Annals of Oncology | 39 | 36 | |
2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 |